Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma-Reference-Cited by-同舟云学术

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma

Published:2021-07-28 Issue:18 Volume:81 Page:4709-4722
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Nesic Ksenija,Kondrashova Olga^ORCID,Hurley Rachel M.,McGehee Cordelia D.,Vandenberg Cassandra J.,Ho Gwo-Yaw^ORCID,Lieschke Elizabeth,Dall Genevieve,Bound Nirashaa,Shield-Artin Kristy,Radke Marc,Musafer Ashan,Chai Zi Qing,Ghamsari Mohammad Reza Eftekhariyan^ORCID,Harrell Maria I.,Kee Damien^ORCID,Olesen Inger,McNally Orla,Traficante Nadia,Australian Ovarian Cancer Study ,DeFazio Anna^ORCID,Bowtell David D.L.,Swisher Elizabeth M.^ORCID,Weroha S. John,Nones Katia^ORCID,Waddell Nicola^ORCID,Kaufmann Scott H.^ORCID,Dobrovic Alexander^ORCID,Wakefield Matthew J.^ORCID,Scott Clare L.^ORCID

Funder

National Health and Medical Research Council

Victorian Cancer Agency

NIH

U.S. Army Medical Research and Materiel Command

NHMRC

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies for the prevention or reversal of PARP inhibitor resistance;Expert Review of Anticancer Therapy;2024-08-20

2. Methylation synthetic lethality: Exploiting selective drug targets for cancer therapy;Cancer Letters;2024-08

3. Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer;Frontiers in Oncology;2024-07-29

4. High-level tumour methylation of BRCA1 and RAD51C is required for homologous recombination deficiency in solid cancers;NAR Cancer;2024-07-09

5. CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer;iScience;2024-07